Drug Interactions between Abecma and ixazomib
This report displays the potential drug interactions for the following 2 drugs:
- Abecma (idecabtagene vicleucel)
- ixazomib
Interactions between your drugs
ixazomib idecabtagene vicleucel
Applies to: ixazomib and Abecma (idecabtagene vicleucel)
Consumer information for this interaction is not currently available.
MONITOR: The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years. In some cases, the neuropathy may progress or become irreversible despite discontinuation of the medications.
MANAGEMENT: Caution is advised during concomitant use of agents with neurotoxic effects. Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage. If feasible, therapy should generally be reinstituted only after resolution of neuropathy symptoms or return of symptoms to baseline status. In some cases, permanent dosage reductions may be required.
Drug and food interactions
ixazomib food
Applies to: ixazomib
Food may interfere with the absorption of ixazomib, which may lead to lower blood levels of the medication and possibly reduced effectiveness. You should take ixazomib at least 1 hour before or 2 hours after eating. On days when you take both ixazomib and dexamethasone, make sure you do not take them at the same time, since ixazomib should be taken on an empty stomach while dexamethasone should be taken with food to prevent irritation and injury to the stomach.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.